PAVmed Triumphs Over Nasdaq Hurdle: What It Means for Investors
PAVmed Inc. achieved compliance with Nasdaq’s stringent continuing listing standards, maintaining its presence on the Nasdaq. The company increased its stockholders’ equity above $2.5 million through strategic financial maneuvers, including deconsolidation of a subsidiary and restructuring of convertible debt. Lucid Diagnostics and Veris Health, PAVmed’s subsidiaries, are driving innovations in the fight against esophageal cancer … Read more